Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.

CONCLUSIONS: Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care. PMID: 31822399 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31822399?dopt=Abstract

Source: Gynecologic Oncology - December 6, 2019 Category: Cancer & Oncology Authors: Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR Tags: Gynecol Oncol Source Type: research